CNX-774 is primarily utilized in the field of medical research, particularly in the study of cancer therapies. It functions as a potent inhibitor targeting the Epidermal Growth Factor Receptor (EGFR), a protein often mutated in various cancers such as lung and colorectal cancer, involved in cancer cell proliferation and survival. Researchers employ CNX-774 to investigate its efficacy in halting tumor growth and inducing apoptosis in malignant cells. Its application extends to preclinical studies where it is tested in various cancer models to assess its potential as a therapeutic agent. Additionally, CNX-774 is used in combination studies with other anticancer drugs to evaluate synergistic effects and enhance treatment outcomes. This chemical, with high specificity for cancer cells over normal cells, helps reduce potential side effects and is tested in laboratory and animal models for efficacy and safety before human use. Ongoing research focuses on developing drug delivery forms, improving treatment efficacy, and evaluating long-term effects to ensure safe and effective patient treatment. CNX-774 plays a crucial role in advancing the development of targeted cancer therapies, offering hope for more effective and personalized treatment options.